Profile data is unavailable for this security.
About the company
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
- Revenue in USD (TTM)66.52m
- Net income in USD-84.05m
- Incorporated2020
- Employees179.00
- LocationRepare Therapeutics Inc7210 Frederick-Banting, Suite 100ST-LAURENT H4S 2A1CanadaCAN
- Websitehttps://www.reparerx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coya Therapeutics Inc | 9.55m | -10.70m | 108.60m | 8.00 | -- | 3.09 | -- | 11.37 | -0.6928 | -0.6928 | 0.687 | 2.10 | 0.4027 | -- | -- | 1,194,290.00 | -45.10 | -- | -49.39 | -- | -- | -- | -111.98 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -28.17m | 111.50m | 140.00 | -- | 35.95 | -- | -- | -1.06 | -1.06 | 0.00 | 0.0579 | 0.00 | -- | -- | 0.00 | -96.37 | -- | -165.17 | -- | -- | -- | -- | -- | -- | -16.57 | 0.8306 | -- | -- | -- | -11.06 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.36m | 112.98m | 54.00 | -- | 0.735 | -- | 7.00 | -1.05 | -1.05 | 0.2977 | 2.59 | 0.0845 | -- | -- | 322,920.00 | -30.03 | -- | -34.41 | -- | 97.06 | -- | -355.24 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 116.19m | 88.00 | -- | 0.7042 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 118.99m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Repare Therapeutics Inc | 66.52m | -84.05m | 119.46m | 179.00 | -- | 0.6828 | -- | 1.80 | -2.00 | -2.00 | 1.56 | 4.12 | 0.270 | -- | 3.95 | 371,642.50 | -34.11 | -23.40 | -40.73 | -26.37 | -- | -- | -126.34 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Invizyne Technologies Inc | 0.00 | -5.12m | 121.10m | 31.00 | -- | -- | -- | -- | -0.6305 | -0.6305 | 0.00 | -0.4431 | 0.00 | -- | -- | 0.00 | -146.70 | -- | -- | -- | -- | -- | -- | -- | -- | -66.29 | -- | -- | -- | -- | -46.00 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -21.24m | 124.99m | 11.00 | -- | 1.65 | -- | -- | -0.8405 | -0.8405 | 0.00 | 2.50 | 0.00 | -- | -- | 0.00 | -43.73 | -232.67 | -54.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 125.28m | 31.00 | -- | 2.42 | -- | 181.83 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 125.58m | 235.00 | -- | -- | 25.86 | 0.4126 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Adverum Biotechnologies Inc | 1.00m | -94.11m | 125.65m | 121.00 | -- | 0.8718 | -- | 125.65 | -6.03 | -6.03 | 0.0585 | 6.93 | 0.0046 | -- | -- | 8,264.46 | -43.66 | -36.39 | -50.24 | -39.04 | -- | -- | -9,411.10 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.60m | 130.41m | 66.00 | -- | 1.43 | -- | -- | -2.07 | -2.07 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -56.88 | -- | -66.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2024 | 10.33m | 24.35% |
| ARK Investment Management LLCas of 30 Sep 2024 | 2.51m | 5.91% |
| Redmile Group LLCas of 30 Sep 2024 | 1.94m | 4.58% |
| Aquilo Capital Management LLCas of 30 Sep 2024 | 989.36k | 2.33% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 453.70k | 1.07% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 447.59k | 1.06% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 249.22k | 0.59% |
| GSA Capital Partners LLPas of 30 Sep 2024 | 240.52k | 0.57% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 187.06k | 0.44% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 181.96k | 0.43% |
